Zealand Pharma Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Copenhagen Denmark (1998)

Organization Overview

First Clinical Trial
2006
NCT00283361
First Marketed Drug
2001
lixisenatide (adlyxin)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Zealand Pharma | ZEALAND PHARMA | Zealand Pharma A/S

Active Ingredients

Marketed Drugs (2)

dasiglucagon (Zegalogue) (2021)

lixisenatide (adlyxin) (2001)

Drugs in Phase 3 Trials (3)

dasiglucagon (Zegalogue) (18 trials)

glepaglutide (9 trials)

glucagon (7 trials)

Drugs in Phase 2 Trials (3)

danegaptide (1 trial)

insulin lispro (humalog) (1 trial)

zp120 (1 trial)

Drugs in Phase 1 Trials (3)

bi 456906 (1 trial)

zp7570 (2 trials)

zp8396 (2 trials)

Drugs in Other Trials (1)

gip (1-42) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Congenital Hyperinsulinism (Phase 3)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Heart Failure (Phase 2)

Hyperinsulinism (Phase 3)

Hypoglycemia (Phase 3)

Infarction (Phase 2)

Inflammatory Bowel Diseases (Phase 1)

Myocardial Infarction (Phase 2)

Renal Insufficiency (Phase 1)

Short Bowel Syndrome (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 35
  • # of Trial APIs: 10